Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2019
Apr. 30, 2018
Apr. 30, 2019
Apr. 30, 2018
Revenue $ 250,000 $ 750,000 $ 250,000 $ 750,000
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion 166,250 500,670 166,250 526,023
Amortization of patents 125,625 81,324 376,875 162,648
Research and development expenses (including non-cash share-based compensation expenses of $655,066 and $155,769, $2,228,845 and $195,826, respectively) 1,269,393 660,193 3,516,665 1,438,066
General and administrative expenses (including non-cash share-based compensation expenses of $666,384 and $175,941, $1,842,769 and $402,857, respectively) 1,281,966 908,767 3,348,422 1,898,803
Impairment in carrying amount of patent asset (Note 1) 418,750
Total operating costs and expenses 2,843,234 2,150,954 7,826,962 4,025,540
Loss from operations (2,593,234) (1,400,954) (7,576,962) (3,275,540)
Interest income 18,300 8,440 35,419 17,552
Loss before income taxes (2,574,934) (1,392,514) (7,541,543) (3,257,988)
Provision for income taxes
Net loss (2,574,934) (1,392,514) (7,541,543) (3,257,988)
Less: Net loss attributable to noncontrolling interest (37,242) (13,980) (122,010) (41,382)
Net loss attributable to common shareholders $ (2,537,692) $ (1,378,534) $ (7,419,533) $ (3,216,606)
Net loss per common share attributable to common shareholders:        
Basic and diluted (in Dollars per share) $ (0.13) $ (0.08) $ (0.38) $ (0.19)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 19,645,140 16,713,091 19,403,933 16,661,083